Status:

COMPLETED

Oxycodone or Standard Pain Therapy in Treating Patients With Cancer Pain

Lead Sponsor:

University Hospitals Bristol and Weston NHS Foundation Trust

Conditions:

Pain

Unspecified Adult Solid Tumor, Protocol Specific

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

RATIONALE: Oxycodone helps lessen pain caused by cancer and may improve quality of life. It is not yet known whether oxycodone works better and is more cost effective than standard therapy in treating...

Detailed Description

OBJECTIVES: Primary * Compare overall pain management in patients with cancer-related pain treated with oxycodone hydrochloride vs standard three-step analgesic therapy. * Compare the health economi...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Diagnosis of cancer
  • Requires regular step-2 analgesia for the management of cancer-related pain
  • PATIENT CHARACTERISTICS:
  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • Must be able to take oral medication
  • Must be willing and able to complete a daily patient assessment booklet (PAB)
  • No history of the following conditions:
  • Depression
  • Personality disorders that may lead to self-harm
  • Admission to the hospital for psychiatric reasons
  • Any other psychological disorder that, in the opinion of the investigator, would preclude study treatment
  • Not at risk of additional CNS depressant effects due to study drugs
  • No known history of alcohol or drug abuse or, in the opinion of the investigator, tendency towards drug abuse or addiction
  • No current abuse of alcohol or drugs
  • No known sensitivity to oxycodone hydrochloride or other opioids
  • No history of a specific or allergic reaction to study drugs
  • No contraindications as a result of adverse drug reaction or drug interactions of oxycodone or other opioid drugs
  • No other condition that, in the opinion of the investigator, would make the patient unsuitable for study participation
  • PRIOR CONCURRENT THERAPY:
  • More than 30 days since prior and no concurrent chemotherapy or radiotherapy
  • At least 2 weeks since prior regular (i.e., 4 times per day) step-2 analgesics
  • More than 3 months since prior regular use of opioids, defined as having a regular prescription of an opioid medication
  • Not planning to undergo cancer-related surgery
  • No other concurrent opioid-based medication other than oxycodone hydrochloride capsules as escape medication (arm II)
  • No concurrent participation in another clinical trial involving a new chemical entity

Exclusion

    Key Trial Info

    Start Date :

    January 1 2004

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    February 1 2006

    Estimated Enrollment :

    30 Patients enrolled

    Trial Details

    Trial ID

    NCT00378937

    Start Date

    January 1 2004

    End Date

    February 1 2006

    Last Update

    August 2 2013

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.